Preparing healthcare companies for success
in the value-based economy

2Q 2018 Access Meter Report
NOW AVAILABLE 

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

Real Endpoints Appoints Jeff Berkowitz, CEO and Director

by Real Endpoints LLC

Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving healthcare landscape, announced today that Jeff Berkowitz, a 20-year veteran of the pharmaceutical, drug distribution, pharmacy and payer industries, has joined the company as CEO and member of the board of directors. Jeff is one of the rare executives whose.....

September 13, 2018

read full press release >

The 2018 FH Global Summit

Speaker: Roger Longman

Real Endpoints LLC

The FH Global Summit is the only conference dedicated to solving global challenges in the care and treatment of familial hypercholesterolemia (FH) through a multi-stakeholder and interdisciplinary approach. An invitation-only event, the summit features a stellar lineup of speakers and panelists who are experts in FH, genomics, precision medicine, alongside leading healthcare practitioners, individuals with FH and industry.

October 1, 2018 -
October 2, 2018

Marina del Rey, CA

event >

AMCP Nexus

Attendee: Real Endpoints team

The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.

October 22, 2018 -
October 25, 2018

Orlando, FL

event >

Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?

by Richard Mark Kirkner

The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?

July 25, 2018

Managed Care

read full article >

Recent Insights

view archive >

July 2, 2018

Defining access potential – Before it’s too late

Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approved

Read full insight article >

June 18, 2018

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder

For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?

read full insight presentation >